Skip to main content
Clinical Trials/NCT00343265
NCT00343265
Completed
Not Applicable

Pilot Randomized Trial of Vaginal Progesterone to Prevent Preterm Birth in Multiple Pregnancy

University of Calgary1 site in 1 country84 target enrollmentJune 2006

Overview

Phase
Not Applicable
Intervention
Vaginal progesterone gel
Conditions
Preterm Birth
Sponsor
University of Calgary
Enrollment
84
Locations
1
Primary Endpoint
Gestational age
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to see if daily use of vaginal progesterone will prevent preterm birth in women carrying 2 or more babies.

Detailed Description

Women who are pregnant with twins or any higher order multiple will be approached to take part. Women will be randomized to get either vaginal progesterone gel or a placebo gel daily from study entry until 35 6/7 weeks. Women can enter the study between 16 - 20 6/7 weeks. Two hundred women will be recruited to take part. Data will be collected on the women and their infants to see if the active medication prolongs pregnancy.

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
March 2011
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Sue Ross

Adjunct Professor

University of Calgary

Eligibility Criteria

Inclusion Criteria

  • Confirmed multiple pregnancy
  • Ultrasound confirmed minimum of 2 live fetuses
  • Gestational age 16-20 6/7 weeks

Exclusion Criteria

  • Placenta previa
  • Pre-existing hypertension
  • Major fetal anomaly
  • Monoamniotic, monozygotic multiples
  • Maternal seizure disorder
  • History of, or active, thromboembolic disease
  • Maternal live disease
  • Breast malignancy or pathology
  • Progesterone dependent neoplasia
  • Plans to move to another city during pregnancy

Arms & Interventions

1

Progesterone gel

Intervention: Vaginal progesterone gel

2

Vaginal gel with no medication

Intervention: Placebo gel

Outcomes

Primary Outcomes

Gestational age

Time Frame: Delivery

Secondary Outcomes

  • Proportion of women delivering < 35 weeks(Delivery)
  • Proportion of women delivering < 37 weeks(Delivery)
  • Proportion of women having spontaneous preterm delivery(Delivery)
  • Proportion of women having tocolytic therapy(During pregnancy)
  • Treatment compliance(Delivery)
  • Length of stay for mother and infants(Discharge)
  • Infant morbidity and mortality(Discharge)
  • Birth weight(Birth)

Study Sites (1)

Loading locations...

Similar Trials